BioMarin Pharmaceuticalvs.Incyte
BMRN vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Incyte is about 2.0× larger than BioMarin Pharmaceutical by market cap; Incyte trades at the lower P/E (16.1 vs 42.6); year to date, Incyte leads (+18.2% vs −0.5%).
Side by side
| BMRN | INCY | |
|---|---|---|
| Market cap | $11.4B | $23.1B |
| Price | $59.12 | $116.71 |
| Today | −1.4% | −1.5% |
| Return YTD | −0.5% | +18.2% |
| Return 1Y | +0.5% | +65.9% |
| P/E | 42.6 | 16.1 |
| P/S | 3.5 | 4.3 |
| P/B | 1.8 | 4.1 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
BioMarin PharmaceuticalBMRN
Biopharma specialized in enzyme and gene therapies for rare genetic diseases.
Full BMRN profile →More comparisons in Biotech & innovation
See where BMRN and INCY sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →